Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

MAPK-driven glioma progression and reprogramming of the tumor-associated immune response.

Neuro-oncology·2026

Same author

Systemic viral vector vaccination induces brain resident memory T cells to drive anti-glioblastoma immunity.

bioRxiv : the preprint server for biology·2026

Same author

In Vivo CAR-Based Immune Cell Engineering: Future Applications and Challenges in Malignant Glioma.

Cancers·2026

Same author

Inhibition of chemokine CXCL12 modulates the tumor microenvironment in glioblastoma and potentiates immune checkpoint inhibitor efficacy in a tissue-specific manner.

Neuro-oncology advances·2026

Same author

Spike-in probe-enhanced single-cell RNA-seq reveals post-infusion transcriptomic remodeling of "prime-and-kill" synNotch-CAR-T cells.

bioRxiv : the preprint server for biology·2026

Same author

Highlights in IO: next-generation CAR-T therapy for glioblastoma.

Journal for immunotherapy of cancer·2026

Same journal

TNF inhibitors for the long-term management of juvenile idiopathic arthritis associated uveitis: real-life data from the ITHACA cohort.

Expert opinion on biological therapy·2026

Same journal

Type 2 inflammation and biologics: a twenty-year journey.

Expert opinion on biological therapy·2026

Same journal

Current outlook on the use of biological agents to improve outcomes in adult secondary hemophagocytic lymphohistiocytosis.

Expert opinion on biological therapy·2026

Same journal

Addressing challenges in disease management of childhood-onset systemic lupus erythematosus: the role of biologics, with primary focus on rituximab and belimumab.

Expert opinion on biological therapy·2026

Same journal

Biological drugs for the treatment of children with atopic dermatitis.

Expert opinion on biological therapy·2026

Same journal

Optimizing biologic therapy in psoriasis: dose adjustment, treatment duration, and tapering-an expert perspective.

Expert opinion on biological therapy·2026

See all related articles

Search research articles

Related Experiment Video

Updated: Mar 17, 2026

Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts

Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts

Published on: September 1, 2018

Cellular immunotherapy for malignant gliomas.

Yi Lin¹, Hideho Okada¹

¹a Neurological Surgery , University of California San Francisco , San Francisco , CA , USA.

Expert Opinion on Biological Therapy

|July 20, 2016

Summary

This summary is machine-generated.

Cellular immunotherapy shows promise for malignant gliomas, with ongoing trials in vaccines and adoptive cell transfer. Further research is needed to improve efficacy and overcome challenges in brain tumor treatment.

Keywords:

CAR-T cell therapy Glioma adoptive cell transfer cellular immunotherapy dendritic cell vaccine

More Related Videos

Isolation and Flow Cytometric Analysis of Glioma-infiltrating Peripheral Blood Mononuclear Cells

Isolation and Flow Cytometric Analysis of Glioma-infiltrating Peripheral Blood Mononuclear Cells

Published on: November 28, 2015

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

Related Experiment Videos

Last Updated: Mar 17, 2026

Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts

Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts

Published on: September 1, 2018

Isolation and Flow Cytometric Analysis of Glioma-infiltrating Peripheral Blood Mononuclear Cells

Isolation and Flow Cytometric Analysis of Glioma-infiltrating Peripheral Blood Mononuclear Cells

Published on: November 28, 2015

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

Area of Science:

Oncology
Immunology
Neuro-oncology

Background:

Cancer immunotherapy has advanced significantly, with cellular therapies emerging as a key strategy.
Malignant gliomas remain challenging to treat, necessitating novel therapeutic approaches.

Purpose of the Study:

To review recent and ongoing cellular immunotherapy studies for malignant gliomas.
To cover cellular vaccine and adoptive cell transfer (ACT) strategies.

Main Methods:

Review of cellular vaccine approaches (tumor cell-based, dendritic cell-based).
Review of ACT strategies including lymphokine-activated killer (LAK) cells, γδ T cells, tumor-infiltrating lymphocytes (TIL), chimeric antigen receptor (CAR)-T cells, and T-cell receptor (TCR) transduced T cells.

Main Results:

Some studies show promising results for cellular immunotherapies in malignant gliomas.
Key areas for improvement include therapeutic production, antigen identification, T-cell trafficking, immune suppression, and imaging interpretation.

Conclusions:

Cellular immunotherapy holds potential for malignant gliomas but requires advancements.
Addressing challenges in production, targeting, immune modulation, and data interpretation is crucial for clinical success.